An update from Island Pharmaceuticals Ltd ( (AU:ILA) ) is now available.
Island Pharmaceuticals Ltd has concluded the follow-up phase of its Phase 2a/b PROTECT clinical trial for ISLA-101, aimed at treating dengue fever. The trial, which includes both preventative and therapeutic arms, has shown promising results with the desired blood concentration levels achieved in all participants. The company expects to receive virus level data by the end of the month, with high-level unblinded results anticipated in May. This progress could strengthen Island’s position in the antiviral market and enhance future regulatory engagements.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on creating treatments for viral diseases. The company’s primary product, ISLA-101, is being tested for its efficacy in treating and preventing dengue fever.
YTD Price Performance: -5.88%
Average Trading Volume: 141,351
Technical Sentiment Signal: Sell
Current Market Cap: A$33.64M
For an in-depth examination of ILA stock, go to TipRanks’ Stock Analysis page.